Eastgate Biotech (ETBI) Inactive 10-Q14 Nov 142014 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2014	Nov. 14, 2014
Document and Entity Information:	'	'
Entity Registrant Name	'EASTGATE ACQUISITIONS CORP	'
Entity Central Index Key	'0001099574	'
Trading Symbol	'esaq	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	78,310,234
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Amendment Flag	'false	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS Unaudited (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current	'	'
Cash	$6,166	$458
Deposits and prepaid assets	40,242	'
Total current assets	46,408	458
Other assets	'	'
Property & Equipment, net	148,477	71,297
Sales tax recoverable	40,546	'
Total other assets	189,023	71,297
Total assets	235,431	71,755
Current liabilities	'	'
Accounts payable and accrued liabilities	248,737	421,439
Accrued liabilities related party	532,493	960,000
Capital lease obligation	'	24,380
Accrued interest - related parties	141,924	95,004
Notes payable - related parties	980,690	898,109
Total current liabilities	1,903,844	2,398,932
Total Liabilities	1,903,844	2,398,932
Stockholders' equity	'	'
Authorized: Preferred stock:50,000,000 shares authorized at $0.00001 par value no shares issued at September 30, 2014 and December 31, 2013	'	'
Authorized: Common stock: 450,000,000 shares authorized at $0.00001 par value 52,615,607 and 31,625,000 shares issued and outstanding at September 30, 2014 and December 31, 2013 respectively	525	316
Additional paid-in capital	4,632,962	134,884
Subscription payable	'	2,000
Accumulated other comprehensive income	12,796	147
Accumulated deficit	-6,314,696	-2,464,524
Total stockholders' Deficit	-1,668,413	-2,327,177
Total liabilities and stockholders' equity	$235,431	$71,755

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS Unaudited (Parentheticals) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	'	'
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	450,000,000	450,000,000
Common stock, issued	52,615,607	31,625,000
Common stock, outstanding	52,615,607	31,625,000

CONSOLIDATED_CONDENSED_STATEME

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS Unaudited (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
REVENUES	'	'	'	'
Cost of goods sold	'	'	'	'
Gross (loss) profit	'	'	'	'
OPERATING EXPENSES	'	'	'	'
Professional fees	22,943	13,370	125,941	26,677
Research & development	308,044	44,757	693,535	107,503
General and administrative	575,604	158,673	2,904,319	449,711
Marketing and selling	23,526	9,327	58,330	9,327
Total Operating Expenses	930,117	226,127	3,782,125	593,218
LOSS FROM OPERATIONS	-930,117	-226,127	-3,782,125	-593,218
Other items	'	'	'	'
Interest expense	-23,112	-18,064	-68,047	-42,987
Total other items	-23,112	-18,064	-68,047	-42,987
LOSS BEFORE INCOME TAXES	-953,229	-244,191	-3,850,172	-636,205
PROVISION FOR INCOME TAXES	'	'	'	'
NET LOSS	-953,229	-244,191	-3,850,172	-636,205
BASIC LOSS PER SHARE (in dollars per share)	($0.02)	($0.01)	($0.09)	($0.02)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING (in shares)	50,204,563	31,625,000	42,974,824	31,625,000
A summary of the components of other comprehensive loss for the periods ended is as follows:	'	'	'	'
Net Loss	-953,229	-244,191	-3,850,172	-636,205
Other Comprehensive Loss - foreign currency translation	-4,497	-37	12,649	-37
Comprehensive Loss	($957,726)	($244,228)	($3,837,523)	($636,242)

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Unaudited (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net loss for the period	($3,850,172)	($636,205)
Adjustments to reconcile net loss to net cash used by operating activities:	'	'
Expenses paid on the Company's behalf by a related party	4,938	177,816
Common stock issued for services	1,263,911	'
Depreciation	18,723	10,461
Services contributed by shareholders	'	'
Changes in operating assets and liabilities:	'	'
Accrued interest	46,920	39,486
Prepaid asset	-40,242	4,500
Accounts payable	-92,294	189,774
Accrued liabilities related party	1,517,962	'
Sales tax recoverable	-40,546	'
Long term deposit	'	-17,625
Cash flows from operating activities	-1,170,800	-231,793
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Purchase of property and equipment	-95,903	-4,648
Cash flows from investing activities	-95,903	-4,648
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Payment of capital lease obligation	-24,380	-29,140
Proceeds from notes payable related party	125,808	190,771
Payments on notes payable related party	-48,166	'
Common stock issued for cash	1,206,500	'
Cash flows from financing activities	1,259,762	161,631
NET INCREASE (DECREASE) IN CASH	-6,941	-74,810
Effect of foreign currency translation adjustments	12,649	1,254
Cash, beginning of the period	458	100,000
Cash, end of the period	6,166	26,444
Supplemental disclosures of cash flow information:	'	'
Cash paid for income taxes	'	'
Cash paid for interest	20,151	3,502
Non Cash Financing activities:	'	'
Capital contribution by officer - payment of related party payable on behalf of company	'	'
Property & equipment purchased under capital lease obligation	'	63,543
Common stock issued to convert liabilities	2,025,876	'
Common stock issued - subscription payable	$2,000	'

CONDENSED_FINANCIAL_STATEMENTS

CONDENSED FINANCIAL STATEMENTS	9 Months Ended
CONDENSED FINANCIAL STATEMENTS	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
CONDENSED FINANCIAL STATEMENTS	'
	NOTE 1 - CONDENSED FINANCIAL STATEMENTS
	The accompanying financial statements have been prepared by the Eastgate Acquisitions Corporation without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at September 30, 2014, and for all periods presented herein have been made.

	Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company's December 31, 2013 audited financial statements. The results of operations for the periods ended September 30, 2014 and 2013 are not necessarily indicative of the operating results for the full years.

GOING_CONCERN

GOING CONCERN	9 Months Ended
GOING CONCERN	Sep. 30, 2014
Going Concern [Abstract]	'
GOING CONCERN	'
	NOTE 2 - GOING CONCERN

	The accompanying financial statements have been prepared in conformity with generally accepted accounting principle, which contemplate continuation of the Company as a going concern. However, the Company has accumulated deficit of $6,314,696 as of September 30, 2014. The Company currently has limited liquidity, and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time, raising substantial doubt about its ability to continue as a going concern.

	Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses The Company intends to position itself so that it may be able to raise additional funds through the capital markets. In light of management's efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern.

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
SIGNIFICANT ACCOUNTING POLICIES	Sep. 30, 2014
Accounting Policies [Abstract]	'
SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES

	Principles of Consolidation
	The consolidated financial statements include the accounts of Eastgate Acquisitions Corporation and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.

	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

	Cash and Cash Equivalents
	For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes.

	Research and Development Costs
	The Company expenses research and development costs to operations as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including employee-related expenses; laboratory supplies and other direct expenses; third-party contractual costs relating to nonclinical studies and related contract manufacturing expenses, development of manufacturing processes and regulatory registration.

	Foreign Currency Translation
	Foreign denominated assets and liabilities of the Company are translated into U.S. dollars at the prevailing exchange rates in effect at the end of the reporting period. Income statement accounts are translated at a weighted average of exchange rates which were in effect during the period. Translation adjustments that arise from translating the foreign subsidiary's financial statements from local currency to U.S. currency are recorded in the other comprehensive loss component of stockholders' equity.

	Recent Accounting Pronouncements
	In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as "Development Stage Entities" (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard and will not report inception to date financial information.

	The Company has evaluated recent accounting pronouncements and their adoption has not had or is not expected to have a material impact on the Company's financial position or statements.

RELATEDPARTY_TRANSACTIONS

RELATED-PARTY TRANSACTIONS	9 Months Ended
RELATED-PARTY TRANSACTIONS	Sep. 30, 2014
Related Party Transactions [Abstract]	'
RELATED-PARTY TRANSACTIONS	'
	NOTE 4 –RELATED-PARTY TRANSACTIONS

	Notes payable – related parties
	The Company has recorded loans from shareholders, amounts due to shareholders for expenses paid on its behalf by shareholders as Notes payable - related parties on the balance sheet. The amounts comprising Notes payable – related parties bear interest ranging from 5 percent per annum to 10 percent per annum, are unsecured and are due and payable upon demand.

	During the nine months ended September 30, 2014 the CEO and companies owned by the CEO as well as a company owned by a related party shareholder have advanced cash to the Company of $125,808, and have had expenses paid by the Company of $4,938 on their behalf. At September 30, 2014 the Company has repaid $48,166 of related party loans. During the year ended December 2013 the CEO and companies owned by the CEO as well as a company owned by a related party shareholder have paid for expenses on behalf of the Company of $81,584 and advanced cash to the Company of $367,422. As of September 30, 2014 and December 31, 2013, the Company owed $141,924 and $95,004 of accrued interest to related parties, respectively, resulting from interest expense of $68,047 and $59,848, respectively.

SALES_TAX_RECOVERABLE

SALES TAX RECOVERABLE	9 Months Ended
SALES TAX RECOVERABLE	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
SALES TAX RECOVERABLE	'
	NOTE 5 –SALES TAX RECOVERABLE

	Sales tax receivable
	The Company recovers sales tax paid, for which returns are filed on annual basis. At September 30, 2014, $40,546 was claimed as recoverable compared to the December 31, 2013 balance of $0. Sales tax recoverable is a result of sales tax paid on eligible expenses.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY

9 Months Ended

Sep. 30, 2014

Equity [Abstract]

STOCKHOLDERS' EQUITY

NOTE 6 – STOCKHOLDERS' EQUITY

On September 15, 2014, the board of directors and the shareholders holding a majority of our common stock approved amending our Restated Articles of Incorporation to 1) change our name to "Eastgate Biotech Corp." from "Eastgate Acquisitions Corporation" and 2) increase our total number of shares of authorized capital stock to 500,000,000 shares consisting of (i) 450,000,000 shares of common stock and (ii) 50,000,000 shares of preferred stock. Also on September 15, 2014 shareholders holding a majority of our common stock approved the Company's 2014 Equity Incentive Plan, which was previously approved by the board of directors on May 20, 2014. The name change and increase in authorized shares will become effective when we amend the Restated Articles of Incorporation by filing a Certificate of Amendment with the Secretary of State of Nevada.

During the quarter ended March 31, 2014 the Company has sold 4,190,000 Units at $0.25 and 450,000 Units at $0.22 consisting of one share of common stock and a warrant to purchase 0.75 of a share for cash pursuant to a private placement agreement. As a result of this transaction, the Company issued 4,640,000 shares of common stock and 3,480,000 warrants to purchase our common stock for five years at $0.25 per share. The Company issued 1,000,000 shares and paid $110,000 in cash in finder's fee in connection with this transaction.

Also, during the quarter ended March 31, 2014 the Company issued 4,660,000 Units consisting of one share of common stock and a warrant to purchase 0.75 of a share in satisfaction of accrued liabilities at the price of $0.25 per share. As a result of this transaction, the Company issued 4,660,000 shares of common stock and 3,495,000 warrants to purchase our common stock for five years at $0.25 per share. The Units were issued on the same terms as the Units issued in connection with the private placement transaction.

Additionally, during the quarter ended March 31, 2014 the Company issued a total of 1,073,000 shares of common stock to employees and consultants for services rendered at the price of $0.25 per share.

During the quarter ended March 31, 2014 the Company issued 321,628 shares of common stock to vendors in satisfaction of accounts payable and accrued liabilities at the price of $0.25 per share.

During the quarter ended June 30, 2014 the Company has sold 244,000 Units consisting of one share of common stock and a warrant to purchase 0.75 of a share for cash pursuant to a private placement agreement at the price of $0.25 per share. As a result of this transaction, the Company issued 244,000 shares of common stock and 183,000 warrants to purchase our common stock for five years at $0.25 per share.

During the quarter ended June 30, 2014 the Company has issued 2,452,400 Units consisting of one share of common stock and a warrant to purchase 0.75 of a share in satisfaction of accrued liabilities at the price of $0.25 per share. As a result of this transaction, the Company issued 2,452,400 shares of common stock and 1,839,300 warrants to purchase our common stock for five years at $0.25 per share. The 2,452,400 Units were issued on the same terms as the Units issued in connection with the private placement transaction.

During the quarter ended June 30, 2014 the Company issued a total of 3,572,000 shares of common stock to consultants for services rendered at the price of $0.25 per share.

During the quarter ended June 30, 2014 the Company issued 280,000 shares of common stock to two officers as part of their compensation at the price of $0.25 per share.

During the quarter ended September 30, 2014 the Company issued a total of 977,233 shares of common stock to consultants for services rendered at the price ranging from $0.06 to $0.50 per share.

During the quarter ended September 30, 2014 the Company issued 1,770,346 shares of common stock to two officers and an employee as part of their compensation at the price of $0.055 per share.

As of September 30, 2014, the Company had 8,997,300 warrants to purchase common stock. All outstanding warrants have a weighted average price of $0.25 per share and have a weighted average remaining life of 4.53 years.

The following table summarizes warrants that are issued, outstanding and exercisable

Warrants Issued & Outstanding

Exercise

Expiration

30-Sep

31-Dec

Price

Date

2014

2013

0.25

14-Mar-19

3,495,000

0.25

21-Mar-19

3,480,000

0.25

6-Jun-19

2,022,300

8,997,300

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
SUBSEQUENT EVENTS	Sep. 30, 2014
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	NOTE 7– SUBSEQUENT EVENTS

	In accordance with ASC 855 Company management reviewed all material events through the date of this report and determined that there are no material subsequent events to report except as described below:
	In October of 2014 the Company issued a total of 1,700,000 shares of common stock to consultants for services rendered at the price of $0.065 per share.

	In October of 2014 the Company has sold 100,000 Units consisting of one share of common stock and a warrant to purchase 0.5 of a share for cash pursuant to a private placement agreement at the price of $0.05 per share. As a result of this transaction, the Company issued 100,000 shares of common stock and 50,000 warrants to purchase our common stock for five years at $0.05 per share.

	In October of 2014 the Company issued a total of 23,894,627 shares of common stock in satisfaction of accrued liabilities at the price of $0.32 per share.

SIGNIFICANT_ACCOUNTING_POLICIE1

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Policies)	Sep. 30, 2014
Accounting Policies [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of Eastgate Acquisitions Corporation and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes.
Research and Development Costs	'
	Research and Development Costs
	The Company expenses research and development costs to operations as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including employee-related expenses; laboratory supplies and other direct expenses; third-party contractual costs relating to nonclinical studies and related contract manufacturing expenses, development of manufacturing processes and regulatory registration.
Foreign Currency Translation	'
	Foreign Currency Translation
	Foreign denominated assets and liabilities of the Company are translated into U.S. dollars at the prevailing exchange rates in effect at the end of the reporting period. Income statement accounts are translated at a weighted average of exchange rates which were in effect during the period. Translation adjustments that arise from translating the foreign subsidiary's financial statements from local currency to U.S. currency are recorded in the other comprehensive loss component of stockholders' equity.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as "Development Stage Entities" (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard and will not report inception to date financial information.

	The Company has evaluated recent accounting pronouncements and their adoption has not had or is not expected to have a material impact on the Company's financial position or statements.

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	9 Months Ended
STOCKHOLDERS' EQUITY (Tables)	Sep. 30, 2014
Equity [Abstract]	'
Summarizes warrants that are issued, outstanding and exercisable	'

					Warrants Issued & Outstanding
	Exercise			Expiration	30-Sep		31-Dec
	Price			Date	2014		2013
		$	0.25	14-Mar-19		3,495,000		-
		$	0.25	21-Mar-19		3,480,000
		$	0.25	6-Jun-19		2,022,300		-

						8,997,300		-

GOING_CONCERN_Detail_Textuals

GOING CONCERN (Detail Textuals) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Going Concern [Abstract]	'	'
Accumulated deficit	($6,314,696)	($2,464,524)

RELATEDPARTY_TRANSACTIONS_Deta

RELATED-PARTY TRANSACTIONS (Detail Textuals) (USD $)	3 Months Ended		9 Months Ended			9 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Notes payable - related parties	Notes payable - related parties
Related Party Transaction [Line Items]	'	'	'	'	'	'	'
Notes payable - related parties interest bearing percentage, minimum	'	'	'	'	'	5.00%	'
Notes payable - related parties interest bearing percentage, maximum	'	'	'	'	'	10.00%	'
Advanced cash to the Company	'	'	$125,808	$190,771	'	$125,808	$367,422
Expenses paid on the Company's behalf by a related party	'	'	4,938	177,816	'	4,938	81,584
Repayment of related party loans	'	'	48,166	'	'	48,166	'
Accrued interest to related parties	141,924	'	141,924	'	95,004	141,924	95,004
Interest expense	$23,112	$18,064	$68,047	$42,987	'	$68,047	$59,848

SALES_TAX_RECOVERABLE_Detail_T

SALES TAX RECOVERABLE (Detail Textuals) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'	'
Sales tax receivable	$40,546	'

STOCKHOLDERS_EQUITY_Summarizes

STOCKHOLDERS' EQUITY - Summarizes warrants that are issued, outstanding and exercisable (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]	'	'
Exercise Price	$0.25	'
Warrants Issued & Outstanding	8,997,300	'
14-Mar-19	'	'
Class of Warrant or Right [Line Items]	'	'
Exercise Price	$0.25	'
Warrants Issued & Outstanding	3,495,000	'
21-Mar-19	'	'
Class of Warrant or Right [Line Items]	'	'
Exercise Price	$0.25	'
Warrants Issued & Outstanding	3,480,000	'
6-Jun-19	'	'
Class of Warrant or Right [Line Items]	'	'
Exercise Price	$0.25	'
Warrants Issued & Outstanding	2,022,300	'

STOCKHOLDERS_EQUITY_Detail_Tex

STOCKHOLDERS' EQUITY (Detail Textuals) (USD $)

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

Sep. 30, 2014

Dec. 31, 2013

Mar. 31, 2014

Jun. 30, 2014

Sep. 30, 2014

Jun. 30, 2014

Sep. 30, 2014

Mar. 31, 2014

Jun. 30, 2014

Employee and Consultant

Vendor

Consultant

Officer

Common stock and warrant unit

Common stock and warrant unit Two

Common stock and warrant unit Three

Common stock and warrant unit Four

Minimum

Maximum

Unit Issued One

Unit Issued Two

Stockholders Equity Note [Line Items]

Total number of shares of authorized capital stock

500,000,000

Common stock, shares authorized

450,000,000

Preferred stock, shares authorized

50,000,000

Number of units issued

4,190,000

450,000

4,660,000

244,000

2,452,400

Number of common stock represents by unit

Number of warrants represents by unit

0.75

Units issue price

0.25

0.22

0.25

Issued shares of common stock

4,640,000

4,660,000

244,000

2,452,400

Number of warrants to purchase common stock

8,997,300

3,480,000

3,495,000

183,000

1,839,300

Exercise price

$0.25

Weighted average life

'4 years 6 months 11 days

'5 years

Issued shares in cash in finders fee

1,000,000

Paid in cash

$110,000

Shares issued for services rendered

1,073,000

3,572,000

977,233

Shares issued in satisfaction of accounts payable and accrued liabilities

321,628

Price per share

$0.25

$0.06

$0.50

$0.25

$0.06

Number of officer

Shares issued as compensation

280,000

1,770,346

SUBSEQUENT_EVENTS_Detail_Textu

SUBSEQUENT EVENTS (Detail Textuals) (USD $)	9 Months Ended		3 Months Ended	9 Months Ended	1 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Sep. 30, 2014	Oct. 31, 2014	Oct. 31, 2014	Oct. 31, 2014
			Consultant	Consultant	Subsequent Event	Subsequent Event	Subsequent Event
						Common stock and warrant unit	Consultant
Subsequent Event [Line Items]	'	'	'	'	'	'	'
Shares issued for services rendered	'	'	3,572,000	977,233	'	'	1,700,000
Price per share	'	'	$0.25	'	$0.32	'	$0.07
Number of units issued	'	'	'	'	'	100,000	'
Number of common stock represents by unit	'	'	'	'	'	1	'
Number of warrants represents by unit	'	'	'	'	'	0.5	'
Units issue price	'	'	'	'	'	0.05	'
Issued shares of common stock	'	'	'	'	'	100,000	'
Number of warrants to purchase common stock	8,997,300	'	'	'	'	50,000	'
Exercise price	$0.25	'	'	'	'	$0.05	'
Weighted average life	'4 years 6 months 11 days	'	'	'	'	'5 years	'
Shares issued in satisfaction of accrued liabilities	'	'	'	'	23,894,627	'	'